Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by Zacks Research to Strong-Buy Rating

Key Points

• Supernus Pharmaceuticals has been upgraded to a strong-buy rating by Zacks Research, increasing investor interest in the stock.
• The stock's average target price has been raised to $43.00, with existing ratings of one strong buy, two buys, and one hold from analysts.
• Recent insider transactions included sales of over 246,000 shares worth approximately $10.7 million, indicating significant insider selling activity during the last 90 days.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other analysts also recently weighed in on the company. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Finally, Piper Sandler raised their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday, August 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Trading Up 3.0%

Shares of SUPN stock opened at $46.13 on Wednesday. The stock has a market cap of $2.59 billion, a P/E ratio of 40.11 and a beta of 0.79. Supernus Pharmaceuticals has a 1 year low of $29.16 and a 1 year high of $46.78. The stock has a 50 day simple moving average of $40.41 and a 200 day simple moving average of $34.94.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 5,369 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00. Following the transaction, the senior vice president owned 15,496 shares of the company's stock, valued at $689,726.96. This trade represents a 47.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 246,506 shares of company stock worth $10,696,144 over the last 90 days. Insiders own 8.80% of the company's stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several large investors have recently bought and sold shares of SUPN. Rubric Capital Management LP bought a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $21,908,000. Armistice Capital LLC grew its holdings in Supernus Pharmaceuticals by 7.4% during the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock worth $170,169,000 after acquiring an additional 360,000 shares during the last quarter. Sofinnova Investments Inc. increased its position in Supernus Pharmaceuticals by 53.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company's stock valued at $25,192,000 after acquiring an additional 278,575 shares during the period. GW&K Investment Management LLC increased its position in Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after acquiring an additional 176,091 shares during the period. Finally, Nuveen LLC bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $4,393,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.